OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
HEART$18.0056

Scandinavian Real Heart AB

Medical Equipment, Supplies & DistributionVerified

The company's capital structure is characterized by a low debt-to-equity ratio of 0.07, indicating a conservative leverage approach. However, the negative operating and net income of -35.5 million SEK and -35.5 million SEK respectively, combined with a negative free cash flow of -63.6 million SEK, suggest significant liquidity pressure. The price-to-book ratio of 2.45 implies that the market is valuing the company at a premium to its book value, despite the negative returns on equity and assets of -56.8% and -48.8% respectively. This premium may reflect expectations of future profitability or market share gains, but current financial performance does not support such optimism. Profitability metrics are well below industry norms, with the company reporting negative returns on both equity and assets. The return on equity of -56.8% and return on assets of -48.8% indicate that the company is not generating returns that cover its cost of capital, which is a critical concern for investors. The industry_config for medical equipment typically emphasizes EBITDA margins and operating cash flow as key performance indicators, both of which are negative for Scandinavian Real Heart AB. This suggests that the company is not only failing to meet industry benchmarks but is also at risk of further financial deterioration if operational improvements are not made. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, such as regulatory changes or economic downturns in the primary operating region. The absence of segment or geographic breakdown in the financial data limits the ability to assess the company's exposure to different markets and product lines, which is a concern for investors seeking to understand the sources of risk and growth potential. The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent financial period. The outlook for the current fiscal year does not provide specific numeric deltas, but the negative operating and net income suggest that the company is not on a path to profitability in the near term. The capital expenditure of -28.3 million SEK indicates ongoing investment in the business, but without corresponding revenue growth, these expenditures may not yield the desired returns. The company's ability to achieve positive cash flow and profitability will be critical to its long-term viability. The risk assessment highlights medium liquidity risk and low dilution risk. The negative free cash flow and negative operating cash flow of -63.6 million SEK and -15.7 million SEK respectively, combined with a current ratio of 2.5, suggest that the company has sufficient short-term assets to cover its liabilities but is not generating positive cash flow from operations. The dilution risk is low, as the number of shares outstanding has not changed between basic and diluted shares, indicating no imminent threat from share issuance. However, the company's negative net cash position after subtracting total debt is a key flag that warrants further investigation. Recent events, including filings and transcripts, are not disclosed in the available data, which limits the ability to assess the company's strategic direction and management's response to financial challenges. The absence of recent events or disclosures may indicate a lack of transparency or a focus on internal operations rather than public communication. Investors should monitor future filings and management statements for insights into the company's financial health and strategic initiatives.

30-day price · HEART(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyScandinavian Real Heart AB
TickerHEART.ST
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Scandinavian Real Heart AB develops and commercializes medical devices for cardiac care, primarily generating revenue through product sales and service contracts.

Classification. The company is classified under the industry "Medical Equipment, Supplies & Distribution" within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

The company's capital structure is characterized by a low debt-to-equity ratio of 0.07, indicating a conservative leverage approach. However, the negative operating and net income of -35.5 million SEK and -35.5 million SEK respectively, combined with a negative free cash flow of -63.6 million SEK, suggest significant liquidity pressure. The price-to-book ratio of 2.45 implies that the market is valuing the company at a premium to its book value, despite the negative returns on equity and assets of -56.8% and -48.8% respectively. This premium may reflect expectations of future profitability or market share gains, but current financial performance does not support such optimism. Profitability metrics are well below industry norms, with the company reporting negative returns on both equity and assets. The return on equity of -56.8% and return on assets of -48.8% indicate that the company is not generating returns that cover its cost of capital, which is a critical concern for investors. The industry_config for medical equipment typically emphasizes EBITDA margins and operating cash flow as key performance indicators, both of which are negative for Scandinavian Real Heart AB. This suggests that the company is not only failing to meet industry benchmarks but is also at risk of further financial deterioration if operational improvements are not made. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, such as regulatory changes or economic downturns in the primary operating region. The absence of segment or geographic breakdown in the financial data limits the ability to assess the company's exposure to different markets and product lines, which is a concern for investors seeking to understand the sources of risk and growth potential. The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent financial period. The outlook for the current fiscal year does not provide specific numeric deltas, but the negative operating and net income suggest that the company is not on a path to profitability in the near term. The capital expenditure of -28.3 million SEK indicates ongoing investment in the business, but without corresponding revenue growth, these expenditures may not yield the desired returns. The company's ability to achieve positive cash flow and profitability will be critical to its long-term viability. The risk assessment highlights medium liquidity risk and low dilution risk. The negative free cash flow and negative operating cash flow of -63.6 million SEK and -15.7 million SEK respectively, combined with a current ratio of 2.5, suggest that the company has sufficient short-term assets to cover its liabilities but is not generating positive cash flow from operations. The dilution risk is low, as the number of shares outstanding has not changed between basic and diluted shares, indicating no imminent threat from share issuance. However, the company's negative net cash position after subtracting total debt is a key flag that warrants further investigation. Recent events, including filings and transcripts, are not disclosed in the available data, which limits the ability to assess the company's strategic direction and management's response to financial challenges. The absence of recent events or disclosures may indicate a lack of transparency or a focus on internal operations rather than public communication. Investors should monitor future filings and management statements for insights into the company's financial health and strategic initiatives.
Key takeaways
  • The company is operating at a loss with negative returns on equity and assets, indicating poor profitability.
  • The low debt-to-equity ratio suggests a conservative capital structure, but the negative free cash flow indicates liquidity pressure.
  • Revenue concentration in a single segment and lack of geographic diversification increase business risk.
  • The company's growth trajectory is uncertain, with no disclosed revenue growth and negative operating and net income.
  • The risk assessment highlights medium liquidity risk and low dilution risk, but the negative net cash position is a key concern.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencySEK
Revenue
Gross profit
Operating income-$35.5M
Net income-$35.5M
R&D
SG&A
D&A
SBC
Operating cash flow-$15.7M
CapEx-$28.3M
Free cash flow-$63.6M
Total assets$72.7M
Total liabilities$10.2M
Total equity$62.5M
Cash & equivalents
Long-term debt$4.5M
Valuation
Market price$18.00
Market cap$153.0M
Enterprise value$157.4M
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B2.5
P/Tangible book2.5
Tangible book$62.5M
Net cash-$4.5M
Current ratio2.5
Debt/Equity0.1
ROA-48.8%
ROE-56.8%
Cash conversion44.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricHEARTActivity
Op margin3.9% medp25 -31.3% · p75 14.4%
Net margin2.4% medp25 -30.5% · p75 11.1%
Gross margin46.7% medp25 28.2% · p75 63.1%
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-4.8% medp25 -11.6% · p75 -2.4%
Debt / equity7.0%17.9% medp25 2.7% · p75 52.2%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 21:25 UTC#abde45b3
Market quoteclose SEK 17.20 · shares 0.01B diluted
no public URL
2026-05-04 21:43 UTC#a833cb6d
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 02:50 UTCJob: 91ce9a9d